Compare 8x8 Inc (EGHT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Illumina, Inc. — how do they compare? 8x8 Inc trades at $1.92 (market cap $279.31M), while Illumina, Inc. trades at $188.83 (market cap $28.32B). The key difference: Illumina, Inc. is far larger — about 101.4× 8x8 Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | ILMN | |
|---|---|---|
Market Cap | $279.31M | $28.32B |
Sector | Technology | Health |
52-Week High | $2.76 | $194.33 |
52-Week Low | $1.59 | $91.00 |
Enterprise Value | $556.99M | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT (8x8, Inc.) trades at $1.89, down 12.9% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $27.21M in 2025 despite revenue of $715.07M, though recent quarters have beaten EPS estimates. Positive news includes AI product launches and industry awards, while analyst consensus is mixed with 39% buy ratings.
Outlook hinges on profitability improvement; projected net income of $2M in 2026 offers potential upside, but high debt and thin margins pose risks. Stock sentiment is cautiously optimistic due to innovation, yet volatility and competitive pressures require monitoring for sustained growth.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
